Literature DB >> 25758940

Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes.

Lauren Walker1, Kirsty E McAleese, Alan J Thomas, Mary Johnson, Carmen Martin-Ruiz, Craig Parker, Sean J Colloby, Kurt Jellinger, Johannes Attems.   

Abstract

Multiple different pathological protein aggregates are frequently seen in human postmortem brains and hence mixed pathology is common. Mixed dementia on the other hand is less frequent and neuropathologically should only be diagnosed if criteria for more than one full blown disease are met. We quantitatively measured the amount of hyperphosphorylated microtubule associated tau (HP-τ), amyloid-β protein (Aβ) and α-synuclein (α-syn) in cases that were neuropathologically diagnosed as mixed Alzheimer's disease (AD) and neocortical Lewy body disease (LBD) but clinically presented either as dementia due to AD or LBD, the latter including dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). Our study group consisted of 28 cases (mean age, 76.11 SE: ±1.29 years; m:f, 17:11) of which 19 were neuropathologically diagnosed as mixed AD/DLB. Clinically, 8 mixed AD/DLB cases were diagnosed as AD (cAD), 8 as DLB (cDLB) and 3 as PDD (cPDD). In addition, we investigated cases that were both clinically and neuropathologically diagnosed as either AD (pure AD; n = 5) or DLB/neocortical LBD (pure DLB; n = 4). Sections from neocortical, limbic and subcortical areas were stained with antibodies against HP-τ, Aβ and α-syn. The area covered by immunopositivity was measured using image analysis. cAD cases had higher HP-τ loads than both cDLB and cPDD and the distribution of HP-τ in cAD was similar to the one observed in pure AD whilst cDLB showed comparatively less hippocampal HP-τ load. cPDD cases showed lower HP-τ and Aβ loads and higher α-syn loads. Here, we show that in neuropathologically mixed AD/DLB cases both the amount and the topographical distribution of pathological protein aggregates differed between distinct clinical phenotypes. Large-scale clinicopathological correlative studies using a quantitative methodology are warranted to further elucidate the neuropathological correlate of clinical symptoms in cases with mixed pathology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25758940     DOI: 10.1007/s00401-015-1406-3

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  76 in total

Review 1.  Neuroimaging in Dementia.

Authors:  Adam M Staffaroni; Fanny M Elahi; Dana McDermott; Kacey Marton; Elissaios Karageorgiou; Simone Sacco; Matteo Paoletti; Eduardo Caverzasi; Christopher P Hess; Howard J Rosen; Michael D Geschwind
Journal:  Semin Neurol       Date:  2017-12-05       Impact factor: 3.420

2.  Network Analysis Identifies Disease-Specific Pathways for Parkinson's Disease.

Authors:  Chiara Monti; Ilaria Colugnat; Leonardo Lopiano; Adriano Chiò; Tiziana Alberio
Journal:  Mol Neurobiol       Date:  2016-12-21       Impact factor: 5.590

Review 3.  A clinicopathological approach to the diagnosis of dementia.

Authors:  Fanny M Elahi; Bruce L Miller
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

4.  Modulating protein amyloid aggregation with nanomaterials.

Authors:  Bo Wang; Emily H Pilkington; Yunxiang Sun; Thomas P Davis; Pu Chun Ke; Feng Ding
Journal:  Environ Sci Nano       Date:  2017-07-28

5.  Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease.

Authors:  Michael C Pace; Guilian Xu; Susan Fromholt; John Howard; Keith Crosby; Benoit I Giasson; Jada Lewis; David R Borchelt
Journal:  Acta Neuropathol       Date:  2018-08-23       Impact factor: 17.088

6.  Impact of Alzheimer's Disease, Lewy Body and Vascular Co-Pathologies on Clinical Transition to Dementia in a National Autopsy Cohort.

Authors:  Jagan A Pillai; Robert S Butler; Aaron Bonner-Jackson; James B Leverenz
Journal:  Dement Geriatr Cogn Disord       Date:  2016-09-14       Impact factor: 2.959

Review 7.  Developing therapeutic vaccines against Alzheimer's disease.

Authors:  Thomas Wisniewski; Eleanor Drummond
Journal:  Expert Rev Vaccines       Date:  2015-12-11       Impact factor: 5.217

8.  Applicability of digital analysis and imaging technology in neuropathology assessment.

Authors:  William D Dunn; Marla Gearing; Yuna Park; Lifan Zhang; John Hanfelt; Jonathan D Glass; David A Gutman
Journal:  Neuropathology       Date:  2015-11-18       Impact factor: 1.906

9.  Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model.

Authors:  Brian Spencer; Paula A Desplats; Cassia R Overk; Elvira Valera-Martin; Robert A Rissman; Chengbiao Wu; Michael Mante; Anthony Adame; Jazmin Florio; Edward Rockenstein; Eliezer Masliah
Journal:  J Neurosci       Date:  2016-07-27       Impact factor: 6.167

Review 10.  Neuropathological assessment of the Alzheimer spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2020-08-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.